Quotient Limited to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Quotient Limited (NASDAQ:QTNT) announced its participation in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Quotient Limited (NASDAQ:QTNT) announced its participation in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. The management team will conduct a fireside chat on February 17, 2022, at 8:00 AM ET. This conference is exclusive to BTIG clients, and those interested in a one-on-one meeting or listening to the live event should contact their BTIG representative. Quotient, with over 30 years in transfusion diagnostics, is committed to reshaping diagnostic practices with its innovative MosaiQ platform, which enhances efficiency and reduces costs for laboratories globally.
Details
News Market Reaction – QTNT
The recorded move for QTNT in the trading session of this news was -3.38%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
JERSEY, Channel Islands, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that the management team will participate in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. As part of the conference, the Company will be conducting a fireside chat on Thursday, February 17, 2022 at 8:00am ET.
BTIG hosted events are intended for prospective and existing BTIG clients only. To request a one-on-one meeting with management or to listen to the live event, please contact your BTIG representative with interest.
About Quotient Limited
Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and create operational cost savings to laboratories around the world. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.
The Quotient logo, Quotient MosaiQ and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
Contact: IR@quotientbd.com; +41 22 545 52 26
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.